Clinical Trial Update: A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants [Phase 1]

View source ↗

Summary

Vaxart completed a Phase 1 study evaluating the safety and immunogenicity of its oral bivalent GI.1/GII.4 norovirus vaccine in healthy lactating women and their…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Infections

Drugs mentioned

• Oral Bivalent GI.1/GII.4 Norovirus Vaccine

Snippet

Sponsor: Vaxart | Conditions: Norovirus Infections | Phase 1 | Status: COMPLETED | Results posted: 2026-04-15